Eagle Pharma's Q4 Earnings Miss Street View On Lower Product Sales

Eagle Pharmaceuticals Inc's EGRX Q4 FY21 sales declined 15% Y/Y to $42.3 million, missing the consensus of $51.08 million.
The sales declined primarily due to lower product sales of Belrapzo and Ryanodex and lower royalty revenue of Bendeka, partially offset by higher product sales of Treakisym.
Q4 2021 Belrapzo sales were $5.5 million, compared to $10.2 million a year ago. Q4 2021 Ryanodex sales declined from $7.9 million to $6.1 million.
The gross margin was 71%, down from 75% a year ago, driven by revenue mix.
The Company posted Q4 adjusted EPS of $0.85, missing the consensus of $0.94, and down from $0.96 million a year ago.
Cash and cash equivalents were $97.7 million, and debt was $26.0 million as of December 31, 2021.
Guidance: Eagle Pharma expects Q1 FY22 sales of $120 million - $130 million, with adjusted EPS of $3.80 - $4.10.
Price Action: EGRX shares traded 2.57% higher at $46.26 on the last check Monday.

Earnings Calendar